#Denmark #Scantox #EJBY #DuplexSeq #LatchBio

Scantox's Launch of the DuplexSeq™ Mutagenesis App

Scantox Group has unveiled its latest innovation in genomic safety analysis—the Scantox DuplexSeq Mutagenesis App. This new app is hosted on a recently upgraded bioinformatics platform, significantly enhancing the capabilities of its DuplexSeq™ Mutagenesis Assay kits and services.

Enhanced Accessibility and Performance

On May 12, 2026, Scantox announced that this launch reinstates customer access to DuplexSeq™ Mutagenesis Assays on robust foundational reagent kits that are expected to be more widely available by the third quarter of 2026. The updated bioinformatics pipeline is designed to support scaling, thereby facilitating a broader application of error-corrected sequencing methodologies in nonclinical mutagenesis assessments.

Matt Tate, PhD, the Chief Business Development Officer at Scantox, emphasized the significance of this upgrade: "The DuplexSeq™ platform is now faster, more accessible, and well-positioned for the expanding role of error-corrected sequencing in genomic safety." With the contributions of Clint Valentine, who originally architected the DuplexSeq™ technology, customers can be assured of the continuity and reliability of the upgraded system.

Solid Foundations in Bioinformatics

Clint Valentine, now Vice President of Operations at Fulcrum Genomics, shared insights on the migration process to the new platform hosted by LatchBio. He noted that the transition was smooth, ensuring that scientific rigor and computational durability remained intact throughout the change. The successful testing against TwinStrand's validation dataset confirmed that both the outputs and the operational integrity of the pipeline would be preserved.

Scantox has handpicked LatchBio for this upgrade based on a thorough evaluation of various bioinformatics platforms. The choice was influenced by LatchBio's user-friendly experience, which is tailored for regulated nonclinical science environments. The DuplexSeq Mutagenesis App offers features such as one-click execution of the verified mutation analysis pipeline, centralized management of data and projects, improved data visualization, and custom reporting for sponsors.

Existing users can conveniently upload historical study data directly onto the new platform, which has been designed to meet the rigorous standards of regulatory compliance. As Kyle Giffin, COO of LatchBio, pointed out, the platform is equipped with critical features such as 21 CFR Part 11 controls, immutable audit trails, and SOC 2 Type II certified infrastructure, addressing essential requirements for data integrity and audit readiness.

Availability of DuplexSeq™ Reagent Kits

The upgraded DuplexSeq™ reagent kits are currently available, with expectations for expanded commercialization in Q3 2026. Scantox is also organizing a live onboarding webinar to facilitate transition for its clients, with registration details available on their official website.

About Scantox

Founded in 1977, Scantox is a leading integrated preclinical Contract Research Organization (CRO) operating across Denmark, Sweden, Austria, and the UK. It specializes in providing comprehensive support for drug development processes, including discovery, regulatory toxicology, pharmaceutical development, and genetic toxicology. Scantox's expertise in CNS pharmacology and Göttingen minipig research makes it a well-respected entity in the field, ensuring high-quality, regulator-ready data for its clients. Scantox is part of Impilo, a prominent Nordic healthcare investment firm.

About LatchBio

Based in San Francisco, LatchBio develops data and pipeline infrastructure tailored for the biotechnology sector. Their solutions empower kit, assay, and instrument providers to implement bioinformatics platforms with robust security measures and compliance with vital industry regulations, ensuring reliability across their offerings.

About Fulcrum Genomics

Fulcrum Genomics specializes in bioinformatics consulting and software development tailored for the genomics field. The company collaborates with biotech and pharmaceutical organizations, leveraging the expertise of industry leaders in genomics and computational biology.

By launching the DuplexSeq Mutagenesis App, Scantox strengthens its commitment to advancing genomic safety assessments, paving the way for improved accuracy and efficiency in the biopharma sector.